WO2011125916A1 - 低アルブミン血症改善用組成物 - Google Patents
低アルブミン血症改善用組成物 Download PDFInfo
- Publication number
- WO2011125916A1 WO2011125916A1 PCT/JP2011/058365 JP2011058365W WO2011125916A1 WO 2011125916 A1 WO2011125916 A1 WO 2011125916A1 JP 2011058365 W JP2011058365 W JP 2011058365W WO 2011125916 A1 WO2011125916 A1 WO 2011125916A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- hypoalbuminemia
- leucine
- isoleucine
- improving
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 208000003623 Hypoalbuminemia Diseases 0.000 title claims abstract description 77
- 238000002360 preparation method Methods 0.000 claims abstract description 56
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 53
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 51
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 48
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 41
- 229960000310 isoleucine Drugs 0.000 claims abstract description 40
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 38
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 36
- 239000004474 valine Substances 0.000 claims abstract description 29
- 239000004480 active ingredient Substances 0.000 claims abstract description 24
- 235000013305 food Nutrition 0.000 claims abstract description 22
- 238000001802 infusion Methods 0.000 claims abstract description 14
- 150000005693 branched-chain amino acids Chemical class 0.000 claims description 32
- 229940024606 amino acid Drugs 0.000 abstract description 22
- 150000001413 amino acids Chemical class 0.000 abstract description 22
- 235000013361 beverage Nutrition 0.000 abstract description 5
- 102000009027 Albumins Human genes 0.000 description 49
- 108010088751 Albumins Proteins 0.000 description 49
- 229960003136 leucine Drugs 0.000 description 35
- 229960004295 valine Drugs 0.000 description 30
- 230000000694 effects Effects 0.000 description 28
- 239000000243 solution Substances 0.000 description 23
- 238000004519 manufacturing process Methods 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- 230000001737 promoting effect Effects 0.000 description 20
- 108020004999 messenger RNA Proteins 0.000 description 19
- 239000002609 medium Substances 0.000 description 17
- 210000003494 hepatocyte Anatomy 0.000 description 16
- 239000000126 substance Substances 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 13
- 208000019423 liver disease Diseases 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 102100021699 Eukaryotic translation initiation factor 3 subunit B Human genes 0.000 description 10
- 101000896557 Homo sapiens Eukaryotic translation initiation factor 3 subunit B Proteins 0.000 description 10
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- KZSNJWFQEVHDMF-UHFFFAOYSA-M valinate Chemical compound CC(C)C(N)C([O-])=O KZSNJWFQEVHDMF-UHFFFAOYSA-M 0.000 description 9
- 239000000654 additive Substances 0.000 description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 102000007562 Serum Albumin Human genes 0.000 description 7
- 108010071390 Serum Albumin Proteins 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 230000000996 additive effect Effects 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000010899 nucleation Methods 0.000 description 6
- -1 patches Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000012085 test solution Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000003042 antagnostic effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- 238000011891 EIA kit Methods 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000011530 RNeasy Mini Kit Methods 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000015110 jellies Nutrition 0.000 description 3
- 239000008274 jelly Substances 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000009331 sowing Methods 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 229930182844 L-isoleucine Natural products 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- 235000019454 L-leucine Nutrition 0.000 description 2
- 229920001543 Laminarin Polymers 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000010724 Wisteria floribunda Nutrition 0.000 description 2
- 229940124532 absorption promoter Drugs 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002394 glycogenic effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OCUSNPIJIZCRSZ-ZTZWCFDHSA-N (2s)-2-amino-3-methylbutanoic acid;(2s)-2-amino-4-methylpentanoic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound CC(C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O OCUSNPIJIZCRSZ-ZTZWCFDHSA-N 0.000 description 1
- KWSUGULOZFMUDH-RITPCOANSA-N (2s,3r)-2-amino-3-methylhexanoic acid Chemical compound CCC[C@@H](C)[C@H](N)C(O)=O KWSUGULOZFMUDH-RITPCOANSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-UHFFFAOYSA-N 2-aminohexanoic acid Chemical compound CCCCC(N)C(O)=O LRQKBLKVPFOOQJ-UHFFFAOYSA-N 0.000 description 1
- OSCCDBFHNMXNME-DSDZBIDZSA-N 4-Hydroxy-L-isoleucine Chemical compound CC(O)[C@H](C)[C@H](N)C(O)=O OSCCDBFHNMXNME-DSDZBIDZSA-N 0.000 description 1
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108700023418 Amidases Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010017807 Gastric mucosal hypertrophy Diseases 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- WXNXCEHXYPACJF-UHFFFAOYSA-N N-acetyl-leucine Chemical compound CC(C)CC(C(O)=O)NC(C)=O WXNXCEHXYPACJF-UHFFFAOYSA-N 0.000 description 1
- JDTWZSUNGHMMJM-UHFFFAOYSA-N N-acetylisoleucine Chemical compound CCC(C)C(C(O)=O)NC(C)=O JDTWZSUNGHMMJM-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 206010059344 Protein-losing gastroenteropathy Diseases 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 102000005922 amidase Human genes 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000024829 digestive system symptom Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- OSCCDBFHNMXNME-UHFFFAOYSA-N gamma-hydroxyisoleucine Natural products CC(O)C(C)C(N)C(O)=O OSCCDBFHNMXNME-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000005227 renal system Anatomy 0.000 description 1
- 238000013215 result calculation Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000010491 tara gum Nutrition 0.000 description 1
- 239000000213 tara gum Substances 0.000 description 1
- 238000012731 temporal analysis Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Definitions
- the present invention relates to a composition for improving hypoalbuminemia, and more particularly to a composition for improving hypoalbuminemia that is suitably used in the form of infusion preparations, oral preparations, foods and drinks, and the like.
- amino acid preparations containing branched chain amino acids For the purpose of improving hypoalbuminemia caused by liver diseases and the like, conventionally, amino acid preparations containing branched chain amino acids have been widely used.
- An amino acid preparation for improving hypoalbuminemia containing such a branched chain amino acid is required to have an albumin production promoting effect as an efficacy index and a reduction in side effects as a safety index.
- the branched chain amino acids include valine, leucine and isoleucine.
- As an example of an amino acid preparation containing all of these valine, leucine and isoleucine as active ingredients for example, Rebact (registered trademark) is widely used. .
- conventional amino acid preparations containing all three types of branched chain amino acids may cause side effects such as nausea, abdominal fullness, diarrhea, constipation, abdominal discomfort, abdominal pain, vomiting, loss of appetite, heartburn. is there. Since these side effects are caused by a large protein load in the living body, there is a possibility that the compliance of conventional amino acid preparations with a large amount of protein may be reduced. That is, from the viewpoint of safety as described above, there are also long-awaited drugs and foods for improving hypoalbuminemia with few side effects and good compliance.
- Japanese Patent No. 3712539 discloses a composition containing only L-valine as an active ingredient for improving or treating hypoalbuminemia associated with a decrease in liver function.
- Such a composition is characterized in that it contains no amino acids other than L-valine as an active ingredient, has few side effects, and can improve liver diseases and the like.
- the conventional amino acid preparation and the composition disclosed in Japanese Patent No. 3712539 cannot sufficiently exhibit the effectiveness expected for the amino acid preparation, particularly the albumin production promoting effect. That is, it can be said that a highly safe amino acid preparation that exhibits a high albumin production promoting effect and has reduced side effects has not yet been provided.
- the present invention has been made in view of these disadvantages, and an object of the present invention is to provide a highly safe composition for improving hypoalbuminemia that exhibits a high albumin production promoting effect and has reduced side effects.
- valine has an antagonistic action (inhibitory action) on the albumin production promoting action of leucine and isoleucine in human hepatocytes. It was found that a composition containing leucine and / or isoleucine as an active ingredient, excluding valine, has a significantly high albumin production promoting effect at the level of human hepatocytes.
- a composition for improving hypoalbuminemia containing a branched chain amino acid as an active ingredient, It contains leucine and / or isoleucine as an active ingredient and is characterized by not containing valine.
- composition for improving hypoalbuminemia substantially does not contain valine, antagonism by valine against the albumin production promoting action of leucine and / or isoleucine, which are other active ingredients, is eliminated. Can effectively exert a high albumin production promoting action in vivo.
- composition for improving hypoalbuminemia substantially does not contain valine as an active ingredient, it can reduce the protein load by the amount of valine, thereby reducing side effects and improving safety. be able to.
- the hypoalbuminemia-improving composition that does not contain an active ingredient amount of valine can greatly reduce the sugar load on liver disease patients who are in an impaired glucose tolerance state, and is also useful for blood glucose management.
- the hypoalbuminemia-improving composition may contain leucine and isoleucine as branched chain amino acids.
- the composition for improving hypoalbuminemia contains both leucine and isoleucine as branched chain amino acids, so that the production promoting action of albumin possessed by leucine and isoleucine can be additionally exhibited. .
- the mass ratio of leucine to isoleucine is preferably from 0.1 to 10.
- action can be effectively exhibited by making mass ratio of leucine with respect to isoleucine into the said range.
- the hypoalbuminemia-improving composition may contain only leucine or isoleucine as a branched chain amino acid.
- leucine or isoleucine as a branched chain amino acid.
- composition for improving hypoalbuminemia is preferably used in the form of an infusion preparation.
- the composition for improving hypoalbuminemia can be rapidly and effectively administered through the blood vessel by making the composition for improving hypoalbuminemia into the form of an infusion preparation.
- the composition for improving hypoalbuminemia is also preferably used in the form of an oral preparation.
- the hypoalbuminemia-improving composition is in the form of an oral preparation, so that the hypoalbuminemia-improving composition can be easily and easily administered without invading the living body. .
- the composition for improving hypoalbuminemia can also be used in the form of food and drink.
- the composition for improving hypoalbuminemia can be administered more easily and simply than in the case of the oral preparation.
- QOL Quality Of Life
- branched chain amino acids are three essential amino acids of leucine, isoleucine and valine, and are a concept including forms of these salts, peptides or derivatives.
- active ingredient means an ingredient contained to the extent that it has an albumin production promoting action alone.
- the composition for improving hypoalbuminemia of the present invention contains a branched chain amino acid as an active ingredient, but since it does not substantially contain valine among the branched chain amino acids, it was used as a preparation or the like.
- the above-mentioned conventional problems are sufficiently achieved because it exerts a high albumin production promoting effect and is highly safe by reducing side effects, and in particular, can substantially reduce the sugar load on liver disease patients with abnormal glucose tolerance. Can be solved.
- the composition for improving hypoalbuminemia is a protein production in the case of decreased ingestion of nutrients due to indigestion or malnutrition, malnutrition after surgery, liver disease such as hepatitis or cirrhosis.
- liver disease such as hepatitis or cirrhosis.
- Hypoalbuminemia caused by systemic edema, onset of burns, etc. can be prevented or ameliorated when a large amount of pleural effusion or ascites is retained.
- the composition for improving hypoalbuminemia can prevent or improve the onset of symptoms such as pulmonary edema, ascites, and edema due to the low albumin state.
- composition for improving hypoalbuminemia contains a branched chain amino acid as an active ingredient, contains leucine and / or isoleucine as an active ingredient, and does not contain valine.
- hypoalbuminemia-improving composition does not substantially contain valine as an active ingredient, the details of the mechanism are unknown, but it has the following effects (A) and (B). I think that.
- Valine is an inhibitor of other active ingredients such as leucine, and is presumed to have an antagonistic action against the albumin production promoting action exhibited by active ingredients such as leucine in vivo. Therefore, the composition for improving hypoalbuminemia can completely eliminate the antagonistic action of valine against the albumin production promoting action of leucine and / or isoleucine by containing substantially no valine as an active ingredient, As a result, it is considered that an active ingredient such as leucine other than valine can effectively exert a high albumin production promoting action in vivo.
- the composition for improving hypoalbuminemia substantially does not contain valine, particularly when used as a preparation, the protein load can be reduced by the amount of valine. Side effects such as digestive system symptoms and renal system symptoms when the conventional amino acid preparation contained therein is administered in vivo can be reduced, and safety can be improved.
- valine is the only glycogenic amino acid that increases blood sugar levels when taken among the three types of branched chain amino acids. If a patient with liver disease takes a conventional amino acid preparation containing valine, a glycogenic amino acid, the patient with liver disease may have a side effect of further increasing blood glucose level after meals.
- the hypoalbuminemia-improving composition does not substantially contain valine as an active ingredient, and thus can substantially reduce the glucose load on liver disease patients who have abnormal glucose tolerance. Is also useful.
- the isomers of the branched chain amino acids are not particularly limited, and examples thereof include L-form, D-form, and DL-form. Among these, it is preferable to use L-shaped branched-chain amino acid isomers having affinity for the synthesis of albumin protein in vivo.
- the form of the branched chain amino acid is not particularly limited, and examples thereof include a pure crystalline amino acid in a free form, a salt thereof, a peptide or a derivative thereof.
- Examples of the salt form of this branched chain amino acid include pharmacologically acceptable salt forms such as sodium salt, potassium salt, hydrochloride and acetate.
- a form of the peptide of a branched chain amino acid what formed the peptide into a branched chain amino acid as a dipeptide, a tripeptide, etc. is mentioned.
- these peptides can be effectively utilized by being hydrolyzed to free amino acids by the action of peptidases in vivo.
- branched chain amino acid derivatives include N-acetyl-DL-leucine, DL-norleucine, N-acetyl-DL-isoleucine, 4-hydroxy-L-isoleucine, ⁇ -methylnorleucine, and the like. These derivatives can be effectively used as free amino acids by the action of in vivo acylases and the like.
- the hypoalbuminemia-improving composition may contain both leucine and isoleucine as branched chain amino acids.
- the composition for improving hypoalbuminemia has an antagonistic action on the albumin producing action of leucine and isoleucine, particularly when used as a preparation. Without effect, the effect of promoting the production of albumin in vivo can be improved effectively.
- the composition for improving hypoalbuminemia may contain leucine or isoleucine alone as a branched chain amino acid.
- leucine or isoleucine alone By containing leucine or isoleucine alone in this way, the composition for improving hypoalbuminemia, particularly when used as a preparation, further reduces the protein load in vivo and effectively reduces side effects. Can be made.
- the above-mentioned composition for improving hypoalbuminemia is intended to be an additively effective improvement of the above-mentioned albumin production promoting effect if, for example, importance is given to the effectiveness in administration to patients with liver diseases, leucine and isoleucine It is good to contain together.
- the composition for improving hypoalbuminemia is intended to effectively reduce side effects by reducing the above-mentioned protein load, and leucine or isoleucine. It is good to contain only. That is, the composition for improving hypoalbuminemia can achieve a balance between effectiveness and safety according to the condition of a patient with liver disease.
- the mass ratio of leucine to isoleucine is preferably from 0.1 to 10, more preferably from 0.5 to 3.0.
- the composition for improving hypoalbuminemia can reliably exhibit the additive improvement effect of the albumin production promoting action described above. .
- the composition for improving hypoalbuminemia can contain an additive in addition to the branched chain amino acid, if necessary, as long as the effects of the present invention are not impaired.
- the additive include pharmaceutically or food hygienically acceptable amino acids, stabilizers, preservatives, solubilizers, pH adjusters, thickeners, antioxidants, coloring agents, fragrances, artificial sweeteners, etc. Is mentioned.
- the amount of these additives can be appropriately set according to the amount of the branched chain amino acid.
- the composition for improving hypoalbuminemia is preferably used in the form of a preparation.
- the form of the preparation is not particularly limited, and examples thereof include infusion preparations, oral preparations, transdermal preparations, suppositories, patches, ointments, haptics, lotions and the like.
- the composition for improving hypoalbuminemia is preferably used in the form of an infusion preparation.
- the hypoalbuminemia-improving composition is in the form of an infusion preparation, so that the hypoalbuminemia-improving composition can be rapidly and effectively administered through the blood vessel. The highest albumin production promoting effect can be exhibited.
- Examples of the above-mentioned infusion preparation include injections and drops.
- these are preferably sterilized and isotonic with blood.
- a diluent for example, water, ethyl alcohol, polyethylene glycol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, Polyoxyethylene sorbitan fatty acid esters and the like can be used, and a sufficient amount of sodium chloride, glucose, or glycerin can be added to adjust the solution to be isotonic with body fluid.
- the said infusion preparation can be stored frozen and can also be preserve
- the above-mentioned infusion preparation preserved by freeze-drying can be used by dissolving again by adding distilled water for injection, sterilized water, etc. at the time of use.
- the composition for improving hypoalbuminemia is also preferably used in the form of an oral preparation.
- the hypoalbuminemia-improving composition is in the form of an oral preparation, so that the hypoalbuminemia-improving composition can be easily and easily administered without invading the living body.
- the albumin production promoting effect in can be fully exhibited.
- the type of oral preparation is not particularly limited, and examples thereof include tablets, powders, granules, fine granules, pills, capsules, troches, chewables, and syrups.
- various carriers known in the field of improving hypoalbuminemia are used.
- Such carriers include lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicic acid and other excipients; water, ethanol, propanol, simple syrup, glucose solution, starch solution, Binders such as gelatin solution, carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, polyvinylpyrrolidone; dry starch, sodium alginate, agar powder, laminaran powder, sodium bicarbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, lauryl sulfate Disintegrating agents such as sodium, stearic acid monoglyceride, starch and lactose; disintegration inhibitors such as sucrose, stearin, cocoa butter and hydrogenated oil; absorption promoters such as quaternary ammonium base and sodium lauryl sulfate; Phosphorus, moisturizing agents such as starch; starch, lactose,
- various carriers known in the field of hypoalbuminemia improvement are used.
- the carrier include excipients such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, kaolin and talc; binders such as gum arabic powder, tragacanth powder, gelatin and ethanol; laminaran and agar.
- the above oral preparation may further contain an additive.
- additives include surfactants, absorption promoters, fillers, extenders, moisturizers, preservatives, stabilizers, emulsifiers, solubilizers, salts that regulate osmotic pressure, and the like, and oral preparations Can be appropriately selected and used depending on the dosage unit form.
- the composition for improving hypoalbuminemia is also suitably used as a form of food or drink.
- the composition for improving hypoalbuminemia can be administered more easily and simply than in the case of the oral preparation, and the effect of promoting albumin production in vivo can be sufficiently achieved. It can be demonstrated.
- the composition for improving hypoalbuminemia is in the form of a food or drink, it can be taken easily and easily in daily life, so that QOL (Quality Of Life) can be improved.
- the above-mentioned food and drink are not particularly limited, and examples thereof include supplements, functional nutritional foods, foods for specified health use, foods for sick people, and the like.
- Examples of the form of the food and drink include beverages such as powder, granules and drinks, tablets containing capsules and chewable agents, and edible films.
- a manufacturing method of these food-drinks unless the effect of this invention is impaired, it does not specifically limit, The method in which those skilled in the art are used for each use can be used.
- the particle size is preferably 20 ⁇ m to 2000 ⁇ m, more preferably about 100 ⁇ m to 1500 ⁇ m, and particularly preferably about 500 ⁇ m to 1000 ⁇ m.
- Such granular food can be ingested together with beverages such as water, tea, juice and the like in a granular state, and can also be dissolved in beverages and ingested.
- the composition for improving hypoalbuminemia of the present invention is not limited to the above embodiment.
- a paste thickener, gelling agent
- the type of the paste is not particularly limited.
- the material include polysaccharides that can be usually used, and these can be used alone or in combination of two or more.
- the ratio of 5 mass parts or less is preferable with respect to 100 mass parts of compositions for improving hypoalbuminemia prepared in a gel or jelly form.
- albumin mRNA and hypoxanthine phosphoribyltransferase 1 (hereinafter abbreviated as “HPRT1”) mRNA Albumin mRNA and HPRT1 mRNA were measured.
- the base sequences of albumin and HPRT1 are registered in GenBank as follows, and each base sequence thereof is in accordance with the registered sequence.
- HPRT1 was measured in the same test as a housekeeping gene as a control.
- the sequence of each primer and probe used for the measurement of albumin is described in Nishimura, M .; , Yoshishitu, H .; Yokoi, T .; Tateno, C.I. , Kataoka, M .; , Horie, T .; Yoshizaki, K .; and Naito, S. : Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized river. Xenobiotica, 35: 877-890 (2005).
- albumin concentration in the medium was measured by Human Albumin EIA Kit (manufactured by Takara Bio Inc.).
- hepatocytes human normal hepatocytes (Human Normal Hepatocytes, Lot. 100, LMP, ONQ and VUA, manufactured by In Vitro Technologies, Inc.) were used.
- ⁇ Reagent> The following reagents and equipment were used. Normal hepatocyte medium kit: Cambrex (Takara Bio Inc.) Hank's Balanced Salt Solution Modified: Sigma, 500 mL HEPES Buffer (1M): 100 mL Sodium Pyruvate Solution (100 mM): 100 mL Acrodisc Syringe Filters: Pall Corporation, product number 4187, 50 pieces Rneasy Mini Kit (50): Qiagen Corporation QIAshredder (50): Qiagen Corporation Yeast tRNA: GIBCO BRL TaqMan One-Step RT-PCR Master Mix Reagents Kit: Applied Biosystems Fast 96-WellReaction Plate (0.1 mL): Applied Biosystems Optical Adhesive Covers: Applied Biosystems 24-well flat bottom plate (collagen type I coat): Asahi Techno Glass Co., Ltd. 15 mL Conical Tube: Falcon Trypan blue: Flow Laboratories LTD. ,
- mRNA is quantified using RT-PCR (Real-time quantitative reverse reverse) using a primer pair and a probe of each sequence shown in Table 1 below (the position of the start codon is in accordance with each registered base sequence). This was performed by transcription-polymerase reaction). Each primer and probe were prepared using an automatic DNA synthesizer.
- the dissolution procedure was performed after dissolving in Buffer A, and then adding 1/10 volume of Buffer A medium.
- (2-4) Ile, Leu, or Val solution The Ile, Leu, or Val solution was dissolved so that the concentration of Ile, Leu, or Val was 60 mM. The dissolution procedure was performed after dissolving in Buffer A, and then adding 1/10 volume of Buffer A medium.
- (2-5) Preparation The test solution having the rebact composition prepared in (2-3) and the Ile, Leu or Val solution prepared in (2-4) were diluted 3-fold using Buffer B, and a 20 mM solution was prepared. did.
- RNA was extracted using QIA shredder and Rneasy Mini Kit. The preparation method using this Kit is described below. At 3, 24, 48, and 72 hours after the start of culture, the medium was removed by suction from each well of the 24-well plate. However, at the time of 0 hours from the start of culturing, hepatocytes were collected in a 15 mL Conical Tube at 2 ⁇ 10 5 cells / tube, centrifuged, and the medium was removed by suction.
- RNA solution was diluted 5-fold with 50 ⁇ g / mL Yeast tRNA solution to obtain a total RNA solution for measurement. All extraction operations were performed at room temperature. A 50 ⁇ g / mL Yeast tRNA solution was prepared by diluting Yeast tRNA with RNase-free distilled water.
- Housekeeping gene (HPRT1) and albumin mRNA were quantified as follows using Applied Biosystems 7500 Fast Sequence Detection System (Applied Biosystems).
- RT-PCR was performed at a rate of 20 ⁇ L / tube using TaqMan One-Step RT-PCR Master Mix Reagents Kit including 300 nM Forward Primer, 900 nM Reverse Primer, and 200 nM TaqMan Probe. 3 ⁇ L of total RNA solution was used. The RT-PCR was performed under the condition that the temperature was maintained at 48 ° C. for 30 minutes, then at 95 ° C. for 10 minutes, and then subjected to 40 cycles of 95 ° C. for 15 seconds and 60 ° C. for 1 minute. The fluorescence intensity was measured for each cycle.
- the reaction vessel was Fast 96-Well Reaction Plate (0.1 mL), and the cover was Optical Adhesive Covers.
- the albumin concentration in the medium was measured by Human Albumin EIA Kit (Takara Bio Inc.).
- Experiment 2 is a result of 4 lots of human hepatocytes, and as in Experiment 1, the secretion amount decreased when Val was contained (see Table 3).
- composition for improving hypoalbuminemia is effective in increasing the ability to synthesize albumin.
- mice were fasted for 3 days to induce hypoalbuminemia, and then each test substance was orally administered for 7 days to measure plasma albumin concentration. Details of this experiment are shown below.
- Val (+) Appropriate amounts of L-leucine weighed to 0.214 g, L-isoleucine weighed to 0.107 g, L-valine weighed to 0.129 g (Peptide Laboratories) and distilled water for injection (Otsuka Pharmaceutical) were 15 mL conical. The mixture was placed in a tube (Nippon Becton Dickinson) and mixed. Dissolve completely to 15 mL.
- mice BALB / cCr Slc, female, 7 weeks old (weight at arrival: 18 g to 20 g) (Japan SLC) were used.
- mice ⁇ Method of administration> The following three groups were provided for the mice.
- valine (+) group and Val ( ⁇ ) group each test substance prepared above was orally administered at a dose of 10 mL / kg / day for 7 consecutive days after fasting for 3 days.
- the Val (+) group and the Val ( ⁇ ) group were fed during the administration period of each test substance.
- the control group was fed only during the entire test period.
- n 3 Isoleucine: 0.071 g / kg / day, Leucine: 0.143 g / kg / day, Valine: 0.086 g / kg / day (Val ( ⁇ ) group)
- Example collection> On the 3rd day from the start of fasting and on the 1st, 3rd, and 7th days from the start of administration of the test substance, about 20 ⁇ L of blood was collected from the above mouse by injuring the fundus with a heparinized Terumo hematocrit capillary tube (Terumo) . The collected blood was ice-cooled, plasma was separated by centrifugation at 12,000 rpm for 10 minutes, and subjected to measurement of plasma albumin.
- Terumo Terumo hematocrit capillary tube
- Plasma albumin concentration was measured with an automatic analyzer DRI-CHEM7000 (Fuji Film Medical) using Fuji Dry Chem Slide ALB-P (Fuji Film Medical). Table 4 shows the concentrations of albumin in mouse plasma up to 7 days after administration of the test substance.
- ⁇ Analysis method> For the value of each measurement item, the average value (mean) ⁇ standard deviation (SD) of each group was determined. Statistical analysis was performed between the Val (+) group and the Val ( ⁇ ) group by Student's t-test and temporal analysis of variance. The significance level of the test was 5% on both sides. Data aggregation was performed with Microsoft Excel 2003 (Microsoft Corporation). EXSAS 7.6 (Arm Systex) was used as statistical analysis software.
- hypoalbuminemia-improving composition of the present invention is suitably used, for example, in the form of preparations such as infusion preparations and oral preparations and foods and drinks.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
分岐鎖アミノ酸を有効成分として含有する低アルブミン血症改善用組成物であって、
有効成分として、ロイシン及び/又はイソロイシンを含有し、バリンを含有しないことを特徴とする。
当該低アルブミン血症改善用組成物は、分岐鎖アミノ酸を有効成分として含有するものであり、有効成分として、ロイシン及び/又はイソロイシンを含有し、バリンを含有しない。
当該低アルブミン血症改善用組成物は、本発明の効果を損なわない範囲で必要に応じ、上記分岐鎖アミノ酸以外に添加剤を含有することができる。この添加剤としては、薬学的又は食品衛生学的に許容できるアミノ酸、安定化剤、防腐剤、可溶化剤、pH調整剤、増粘剤、酸化防止剤、着色料、香料、人工甘味料等が挙げられる。これらの添加剤の配合量は、上記分岐鎖アミノ酸の配合量に従って適宜設定することができる。
当該低アルブミン血症改善用組成物は、製剤の形態で好適に使用される。かかる製剤の形態としては、特に限定されず、例えば輸液製剤、経口製剤、経皮吸収型製剤、坐剤、貼付剤、軟膏剤、ハップ剤、ローション剤等の形態が挙げられる。
当該低アルブミン血症改善用組成物は、飲食品の形態としても好適に使用される。このように当該低アルブミン血症改善用組成物を飲食品の形態として用いることで、上記経口製剤の場合と比較してより一層容易かつ簡便に投与でき、生体内におけるアルブミン産生促進効果を十分に発揮させることができる。さらに、当該低アルブミン血症改善用組成物を飲食品の形態とすることで、日常生活の中で特に容易かつ簡便に摂取できることから、QOL(Quality Of Life)の向上を図ることができる。
この試験はヒト初代培養肝細胞系において、各被験液で培養することによるアルブミンmRNAの発現能の変化と分泌されるアルブミン量の変化を調べたものであり、以下の通り実施した。
(1)アルブミンmRNA及びhypoxanthine phosphoribosyltransferase 1(以下「HPRT1」と略す)mRNA
アルブミンmRNA及びHPRT1mRNAを測定した。アルブミンとHPRT1の塩基配列は、以下の通りGenBankに登録されており、それらの各塩基配列は登録された配列に従うものである。
アルブミン;GenBank accession number XM 031322
HPRT1;GenBank accession number NM 000194
培地中のアルブミン濃度は、Human Albumin EIA Kit(タカラバイオ株式会社製)により測定した。
以下の物質を利用した。
イソロイシン(Ile):MW131.17
ロイシン(Leu):MW131.17
バリン(Val):MW117.15
肝細胞としては、ヒト正常肝細胞(Human Normal Hepatocytes,Lot.100、LMP、ONQ及びVUA, In Vitro Technologies,Inc.社製)を利用した。
以下の試薬及び器機を利用した。
正常肝細胞専用培地キット:Cambrex社(タカラバイオ株式会社)
Hank’s Balanced Salt solution Modified:シグマ社、500mL
HEPES Buffer(1M):100mL
Sodium Pyrvate Solution(100mM):100mL
Acrodisc Syringe Filters:Pall Corpration、製品番号4187、50個入り
Rneasy Mini Kit(50):キアゲン株式会社
QIAshredder(50):キアゲン株式会社
Yeast tRNA:GIBCO BRL
TaqMan One-Step RT-PCR Master Mix Reagents Kit:Applied Biosystems
Fast 96-WellReaction Plate(0.1mL):Applied Biosystems
Optical Adhesive Covers:Applied Biosystems
24ウエル平底プレート(コラーゲンタイプIコート):旭テクノグラス株式会社
15mL Conical Tube:Falcon
Trypan blue:Flow Laboratories LTD.、0.4% solution in 0.85% saline
β-メルカプトエタノール:シグマ社
Human Albumin EIA Kit:タカラバイオ株式会社
(1)50μg/mLのYeast tRNA液の調製
Yeast tRNAは、RNaseフリーの水で希釈し、50μg/mLとした。
(2-1)Buffer A
Buffer Aとして、Hank’s Balanced Salt solution Modified:HEPES Buffer(1M):Sodium Pyrvate Solution(100mM)を100:1:2の比率で混合した。
(2-2)Buffer B
Buffer Bとして、Buffer A:培地を9:1の比率で混合した。
(2-3)リーバクト組成の被験液
リーバクト組成の被験液として、Ile、Leu、Valの混合後の濃度がそれぞれ13.8mM、27.7mM、18.5mM(リーバクト組成の被験液の濃度として60mM)となるように溶解した。なお、溶解の手順はBuffer Aに溶解後、Buffer Aの1/10量の培地を添加した。
(2-4)Ile、Leu又はVal溶液
Ile、Leu又はVal溶液として、Ile、Leu又はValの濃度が60mMとなるように溶解した。なお、溶解の手順はBuffer Aに溶解後、Buffer Aの1/10量の培地を添加した。
(2-5)調整
(2-3)で調製したリーバクト組成の被験液及び(2-4)で調整したIle、Leu又はVal溶液を、Buffer Bを用いて3倍希釈し、20mMの溶液とした。
Nishimuraらの方法(Nishimura,M.,Yoshitsugu,H.,Naito,S.and Hiraoka,I.:Evaluation of gene induction of drug-metabolizingenzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR.Yakugaku Zasshi,122:339-361(2002))に従い、24wellのプレートに1×105cells/400μL/wellずつ分注し、CO2インキュベーターで培養し、3時間後に培地交換をした。その21時間後(播種開始時点から24時間後)に培地交換した。以後、24時間毎に培地交換を行った。なお、交換する培地の液量は、400μL/wellとした。また、各被験液への交換は、48時間後の培地交換時点で行った。
ヒト肝細胞を播種(1×105 viable cells/0.4mL/well)した後、播種開始時点から3時間後及び24時間後に培地交換を行った。なお、かかる播種時における生存率は90.4%(Lot 100)であった。次いで、播種開始から48時間後に供試験用物質を添加し、この試験物質の添加開始から24時間後にTotal RNAを抽出し(Rneasy Mini Kit使用)、リアルタイムRT-PCRによりアルブミン及びHPRT1のmRNAの定量を行った。なお、HPRT1は、ハウスキーピング遺伝子であり、内部標準として用いた。
ヒト肝細胞を播種(1×105 viable cells/0.4mL/well)した後、播種開始時点から3時間後及び24時間後に培地交換を行った。なお、かかる播種時における生存率は93.6%(Lot 100)、84.2%(Lot LMP)、90.0%(Lot QNQ)、84.3%(Lot VUA)であった。次いで、播種開始から48時間後に供試験用物質を添加し、この試験物質の添加開始から24時間後に培地を採取し、分泌されたアルブミン量を定量した。
培地を吸引後、QIA shredder及びRneasy Mini Kitを用いてTotal RNAを抽出した。以下に、このKitを用いた調製方法を記述する。培養開始後3、24、48及び72時間時点において、24 wellのプレートの各wellから培地を吸引除去した。ただし、培養開始0時間時点については15mLのConical Tubeに2×105cells/tubeとなるように肝細胞を分取し、遠心後、培地を吸引除去した。次に、β-メルカプトエタノールを含むRLT溶液(RLT溶液:β-メルカプトエタノール=1:100)を400μLずつ添加し、ピペッティング後、QIA shredder columnに全量を添加し、15,000rpmで2分間遠心した。溶出液350μLを分取し、等量の70%エタノール溶液を添加した。10秒間の攪拌を3回行った後、Rneasy Mini spin columnに全量を添加し、12,000rpmで30秒間遠心し、Collection tube内の溶出液を吸引除去した。700μLのRW1溶液を添加し、12,000rpmで30秒間遠心後、Collection tubeを取りかえた。500μLのRPE溶液を添加し、12,000rpmで30秒間遠心後、Collection tube内の溶出液を吸引除去した。500μLのRPE溶液を添加し、15,000rpmで2分間遠心後、1.5mLのCollection tubeに交換し、50μLのRnase free waterを添加し、10,000rpmで1分間遠心によりtotal RNAを溶出させた。溶出液は50μg/mLのYeast tRNA液を用いて5倍希釈して測定用Total RNA溶液とした。なお、抽出操作は全て室温で行なった。また、50μg/mLのYeast tRNA液は、Yeast tRNAをRNaseフリーの蒸留水で希釈して調製した。
Applied Biosystems 7500 Fast Sequence Detection System(Applied Biosystems)を利用してハウスキーピング遺伝子(HPRT1)及びアルブミンのmRNAを、以下の通り定量した。
培地中のアルブミン濃度はHuman Albumin EIA Kit (タカラバイオ株式会社)により測定した。
(1)mRNAの定量
HPRT1のmRNAを内在性コントロールとした。各mRNAの定量値は、ΔCt法(Nishimura,M.,Yaguri,H.,Yoshitsugu,H.,Naito,S.&Satoh,T.,(2003)Yakugaku Zasshi,123,369-375)にて算出し、試験はtriplicateで行った。アルブミンmRNAの発現量は、HPRT1mRNAの発現量を1とした時の比で表し、その平均値(mean)±標準偏差(SD)を表2及び図1に示した。
結果はLot別の値及び平均値(mean)±標準偏差(SD)で表示した。
得られた結果を表2、表3及び図1に示す。
この試験は、低アルブミン血症を発症したマウスの血漿中アルブミン濃度に対する各試験物質の効果を調べたものであり、以下の通り実施した。
BALB/c、雌性マウスを3日間絶食させ、低アルブミン血症を誘発させた後、各試験物質を7日間経口投与し血漿中アルブミン濃度を測定した。以下に、本実験の詳細を示す。
Val(+):
0.214gに秤量したL-ロイシン、0.107gに秤量したL-イソロイシン及び0.129gに秤量したL-バリン(以上、ペプチド研究所)と注射用蒸留水(大塚製薬)の適量を15mLコニカルチューブ(日本ベクトン・ディッキンソン社)に入れ、混和した。完全に溶解させて15mLとした。
Val(-):
0.214gに秤量したL-ロイシン及び0.107gに秤量したL-イソロイシン(以上、ペプチド研究所)と注射用蒸留水(大塚製薬)の適量を15mLコニカルチューブ(日本ベクトン・ディッキンソン社)に入れ、混和した。完全に溶解させて15mLとした。
本実験には、マウス、BALB/cCr Slc、雌性、7週齢(入荷時体重18g~20g)(日本エスエルシー社)を用いた。
上記マウスに対して、下記の3群を設けた。下記バリン(+)群及びVal(-)群に対しては、3日間の絶食後、上記調製した各試験物質を10mL/kg/日の投与量で7日間連続して経口投与した。なお、Val(+)群及びVal(-)群に対しては、各試験物質の投与期間中は摂餌を行った。また、対照群に対しては、全試験期間中、摂餌のみを行った。
3日間の絶食後、Val(+)を経口投与させる群、n=3
イソロイシン:0.071g/kg/日、
ロイシン:0.143g/kg/日、
バリン:0.086g/kg/日
(Val(-)群)
3日間の絶食後、Val(-)を経口投与させる群、n=5
イソロイシン:0.071g/kg/日、
ロイシン:0.143g/kg/日
(対照群)
試験期間中摂餌させる群、n=5
上記マウスに対して、絶食開始3日目、試験物質投与開始1、3、7日目に、無麻酔下で眼底をヘパリン処理したテルモヘマトクリット毛細管(テルモ社)で傷つけ、約20μL採血を行った。採血した血液は氷冷し、12000rpm、10分間の遠心分離により血漿を分離し、血漿中アルブミン測定に供した。
血漿中アルブミン濃度は、富士ドライケムスライドALB-P(富士フイルムメディカル社)を用いて自動分析装置DRI-CHEM7000(富士フイルムメディカル社)にて測定した。試験物質投与後7日目までのマウス血漿中アルブミン濃度を表4に示した。
各測定項目の値について、各群の平均値(mean)±標準偏差(S.D.)を求めた。また、統計解析は、Val(+)群及びVal(-)群間で、Studentのt-検定及び経時型分散分析により行った。なお、検定の有意水準は両側5%とした。データ集計は、Microsoft Excel 2003(マイクロソフト社)で行った。統計解析ソフトは、EXSAS 7.6(アームシステックス社)を使用した。
表4に示す通り、本条件下で7日間、絶食後のマウスに試験物質を与えたところ、7日目では、Val(+)群に比してVal(-)群のアルブミン上昇傾向(p=0.0531)を認めた。また、補足として経時型分散分析を行ったところ、群と時間で有意差を認め、Val(-)がVal(+)に比して経時的に血漿中アルブミン濃度を上昇させる可能性が示唆された。本試験の結果より、Valを除くこと(Val(-))で、現在臨床で使用されているリーバクト(登録商標)等のBCAA製剤(Val(+))を凌駕する血中アルブミン濃度上昇効果が期待できると考えられた。
Claims (7)
- 分岐鎖アミノ酸を有効成分として含有する低アルブミン血症改善用組成物であって、
有効成分として、ロイシン及び/又はイソロイシンを含有し、バリンを含有しないことを特徴とする低アルブミン血症改善用組成物。 - 上記分岐鎖アミノ酸として、ロイシン及びイソロイシンを含有する請求項1に記載の低アルブミン血症改善用組成物。
- 上記イソロイシンに対するロイシンの質量比が0.1以上10以下である請求項2に記載の低アルブミン血症改善用組成物。
- 上記分岐鎖アミノ酸として、ロイシン又はイソロイシンのみを含有する請求項1に記載の低アルブミン血症改善用組成物。
- 輸液製剤の形態である請求項1に記載の低アルブミン血症改善用組成物。
- 経口製剤の形態である請求項1に記載の低アルブミン血症改善用組成物。
- 飲食品の形態である請求項1に記載の低アルブミン血症改善用組成物。
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2011236979A AU2011236979B2 (en) | 2010-04-07 | 2011-03-31 | Composition for amelioration of hypoalbuminemia |
KR1020127028016A KR101956528B1 (ko) | 2010-04-07 | 2011-03-31 | 저알부민혈증 개선용 조성물 |
SG2012073953A SG184451A1 (en) | 2010-04-07 | 2011-03-31 | Composition for amelioration of hypoalbuminemia |
EP11765816.1A EP2556828B1 (en) | 2010-04-07 | 2011-03-31 | Composition for amelioration of hypoalbuminemia |
CA2793951A CA2793951C (en) | 2010-04-07 | 2011-03-31 | A composition comprising leucine and isoleucine for amelioration of hypoalbuminemia |
CN201180016591.6A CN102858334B (zh) | 2010-04-07 | 2011-03-31 | 低白蛋白血症改善用组合物 |
US13/638,358 US20130059913A1 (en) | 2010-04-07 | 2011-03-31 | Composition for amelioration of hypoalbuminemia |
NZ602642A NZ602642A (en) | 2010-04-07 | 2011-03-31 | Composition for amelioration of hypoalbuminemia |
KR1020177018747A KR20170083160A (ko) | 2010-04-07 | 2011-03-31 | 저알부민혈증 개선용 조성물 |
JP2012509620A JP5483775B2 (ja) | 2010-04-07 | 2011-03-31 | 低アルブミン血症改善用組成物 |
RU2012146985/15A RU2558792C2 (ru) | 2010-04-07 | 2011-03-31 | Композиция для улучшения состояния при гипоальбуминемии |
HK13104619.8A HK1177432A1 (zh) | 2010-04-07 | 2013-04-16 | 低白蛋白血症改善用組合物 |
US14/287,954 US9693982B2 (en) | 2010-04-07 | 2014-05-27 | Composition for amelioration of hypoalbuminemia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-089077 | 2010-04-07 | ||
JP2010089077 | 2010-04-07 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/638,358 A-371-Of-International US20130059913A1 (en) | 2010-04-07 | 2011-03-31 | Composition for amelioration of hypoalbuminemia |
US14/287,954 Division US9693982B2 (en) | 2010-04-07 | 2014-05-27 | Composition for amelioration of hypoalbuminemia |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011125916A1 true WO2011125916A1 (ja) | 2011-10-13 |
Family
ID=44762854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/058365 WO2011125916A1 (ja) | 2010-04-07 | 2011-03-31 | 低アルブミン血症改善用組成物 |
Country Status (14)
Country | Link |
---|---|
US (2) | US20130059913A1 (ja) |
EP (1) | EP2556828B1 (ja) |
JP (1) | JP5483775B2 (ja) |
KR (2) | KR101956528B1 (ja) |
CN (1) | CN102858334B (ja) |
AU (1) | AU2011236979B2 (ja) |
CA (1) | CA2793951C (ja) |
HK (1) | HK1177432A1 (ja) |
MY (1) | MY160626A (ja) |
NZ (1) | NZ602642A (ja) |
RU (1) | RU2558792C2 (ja) |
SG (1) | SG184451A1 (ja) |
TW (1) | TWI499413B (ja) |
WO (1) | WO2011125916A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017101002A (ja) * | 2015-12-04 | 2017-06-08 | イーエヌ大塚製薬株式会社 | 腹水貯留改善用栄養組成物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62135420A (ja) * | 1985-12-09 | 1987-06-18 | Morio Kasai | アミノ酸輸液 |
JP3712539B2 (ja) | 1997-09-30 | 2005-11-02 | 中外製薬株式会社 | 肝疾患治療剤 |
JP2008088113A (ja) * | 2006-10-03 | 2008-04-17 | Ss Pharmaceut Co Ltd | 美白組成物 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2013026C3 (de) * | 1970-03-19 | 1981-01-29 | Wagner, Karl-Heinz, Prof. Dr.Med.Habil., 6300 Giessen | Mittel zur Behandlung und Verhütung von Leberkrankheiten und muskulärer Insuffizienz |
CH580058A5 (ja) * | 1974-01-21 | 1976-09-30 | Maggi Ag | |
JPH06312923A (ja) | 1993-04-30 | 1994-11-08 | Green Cross Corp:The | 末梢静脈投与用栄養輸液 |
US6713501B1 (en) * | 1998-03-13 | 2004-03-30 | The Johns Hopkins University | Supplement for dialysis patients |
US6203820B1 (en) * | 1998-05-28 | 2001-03-20 | Brice E. Vickery | Compositions and methods for enhancing protein anabolism and detoxification |
CN1482905A (zh) * | 2000-12-26 | 2004-03-17 | ������ҩ��ʽ���� | 口腔用组合物 |
US7311925B2 (en) * | 2001-01-22 | 2007-12-25 | Michael A Zasloff | Methods and compositions for blocking microbial adherence to eukaryotic cells |
ITMI20011732A1 (it) | 2001-08-07 | 2003-02-07 | Indena Spa | Composizioni farmaceutiche e/o cosmetiche orali per il trattamento e la prevenzione di disturbi del cuoio capelluto |
DK1638586T3 (da) | 2003-05-14 | 2008-06-23 | Indus Biotech Pvt Ltd | Synergistisk sammensætning til behandling af diabetes mellitus |
KR20150055100A (ko) * | 2004-07-14 | 2015-05-20 | 아지노모토 가부시키가이샤 | C형 간염 바이러스 양성 사람 간경변 환자용 간암 발생·진전 억제제 |
US20060115556A1 (en) * | 2004-12-01 | 2006-06-01 | Foulger Sidney W | Nutritional supplement drink containing xanthone extracts |
EP1938813A1 (en) * | 2005-08-04 | 2008-07-02 | Ajinomoto Co., Inc. | Agent for reduction of oxidized albumin level |
-
2011
- 2011-03-31 NZ NZ602642A patent/NZ602642A/en not_active IP Right Cessation
- 2011-03-31 US US13/638,358 patent/US20130059913A1/en not_active Abandoned
- 2011-03-31 KR KR1020127028016A patent/KR101956528B1/ko active IP Right Grant
- 2011-03-31 CN CN201180016591.6A patent/CN102858334B/zh not_active Expired - Fee Related
- 2011-03-31 SG SG2012073953A patent/SG184451A1/en unknown
- 2011-03-31 AU AU2011236979A patent/AU2011236979B2/en not_active Ceased
- 2011-03-31 JP JP2012509620A patent/JP5483775B2/ja not_active Expired - Fee Related
- 2011-03-31 RU RU2012146985/15A patent/RU2558792C2/ru active
- 2011-03-31 CA CA2793951A patent/CA2793951C/en not_active Expired - Fee Related
- 2011-03-31 MY MYPI2012700722A patent/MY160626A/en unknown
- 2011-03-31 WO PCT/JP2011/058365 patent/WO2011125916A1/ja active Application Filing
- 2011-03-31 KR KR1020177018747A patent/KR20170083160A/ko not_active Application Discontinuation
- 2011-03-31 EP EP11765816.1A patent/EP2556828B1/en not_active Not-in-force
- 2011-04-07 TW TW100112031A patent/TWI499413B/zh not_active IP Right Cessation
-
2013
- 2013-04-16 HK HK13104619.8A patent/HK1177432A1/zh not_active IP Right Cessation
-
2014
- 2014-05-27 US US14/287,954 patent/US9693982B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62135420A (ja) * | 1985-12-09 | 1987-06-18 | Morio Kasai | アミノ酸輸液 |
JP3712539B2 (ja) | 1997-09-30 | 2005-11-02 | 中外製薬株式会社 | 肝疾患治療剤 |
JP2008088113A (ja) * | 2006-10-03 | 2008-04-17 | Ss Pharmaceut Co Ltd | 美白組成物 |
Non-Patent Citations (9)
Title |
---|
CHIORI IJICHI, ET AL.: "Branched-chain amino acids promote albumin synthesis in rat primary hepatocytes through the mTOR signal transduction system", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 303, 2003, pages 59 - 64, XP008162560 * |
KAZUTOMO LMAHORI ET AL., SEIKAGAKU JITEN, 2002, pages 67 - 68, XP008162576 * |
M. OKITA, ET AL.: "Effects of valine on 15N incorporation into serum and tissue protein and non-protein fractions following 15N-L-leucine administration to normal and liver-injured rats.", J. NUTR. SCI. VITAMINOL., vol. 35, no. 6, 1989, pages 559 - 567, XP008162570 * |
NISHIMURA, M.; NAITO, S.; YOKOI, T.: "Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies", DRUG METAB. PHARMACOKINET., vol. 19, 2004, pages 135 - 149 |
NISHIMURA, M.; YAGURI, H.; YOSHITSUGU, H.; NAITO, S.; SATOH, T., YAKUGAKU ZASSHI, vol. 123, 2003, pages 369 - 375 |
NISHIMURA, M.; YOSHITSUGU, H.; NAITO, S.; HIRAOKA, I.: "Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR", YAKUGAKU ZASSHI, vol. 122, 2002, pages 339 - 361 |
NISHIMURA, M.; YOSHITSUGU, H.; YOKOI, T.; TATENO, C.; KATAOKA, M.; HORIE, T.; YOSHIZATO, K.; NAITO, S.: "Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized liver", XENOBIOTICA, vol. 35, 2005, pages 877 - 890 |
OKAYAMA PREFECTURAL JUNIOR COLLEGE KIYO, vol. 33, no. 2, 1990, pages 51 - 54, XP008162572 * |
TOMOAKI TOMIYA, ET AL.: "Treatment with leucine stimulates the production of hepatocyte growth factor in vivo", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 322, no. 3, 24 September 2004 (2004-09-24), pages 772 - 777, XP004536454 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017101002A (ja) * | 2015-12-04 | 2017-06-08 | イーエヌ大塚製薬株式会社 | 腹水貯留改善用栄養組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP2556828B1 (en) | 2017-08-02 |
CN102858334B (zh) | 2016-04-13 |
SG184451A1 (en) | 2012-11-29 |
KR101956528B1 (ko) | 2019-03-13 |
CA2793951C (en) | 2017-04-04 |
US9693982B2 (en) | 2017-07-04 |
AU2011236979A2 (en) | 2012-12-06 |
EP2556828A4 (en) | 2016-01-06 |
KR20170083160A (ko) | 2017-07-17 |
US20130059913A1 (en) | 2013-03-07 |
RU2558792C2 (ru) | 2015-08-10 |
NZ602642A (en) | 2014-07-25 |
TW201204348A (en) | 2012-02-01 |
CA2793951A1 (en) | 2011-10-13 |
MY160626A (en) | 2017-03-15 |
CN102858334A (zh) | 2013-01-02 |
JPWO2011125916A1 (ja) | 2013-07-11 |
RU2012146985A (ru) | 2014-05-20 |
JP5483775B2 (ja) | 2014-05-07 |
EP2556828A1 (en) | 2013-02-13 |
AU2011236979B2 (en) | 2016-05-19 |
TWI499413B (zh) | 2015-09-11 |
KR20130038849A (ko) | 2013-04-18 |
US20140309306A1 (en) | 2014-10-16 |
AU2011236979A1 (en) | 2012-10-18 |
HK1177432A1 (zh) | 2013-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080038321A1 (en) | Prophylactic/therapeutic compositions for liver diseases | |
WO2007004613A1 (ja) | 炎症性腸疾患治療薬及びTNF-α産生抑制剤 | |
JP2004182630A (ja) | 持続性筋肉疲労改善剤 | |
JP6293099B2 (ja) | ジンセノサイドf2の肝疾患予防又は治療用途 | |
US10183040B2 (en) | Method for regulation of lipid metabolism | |
WO2002060431A1 (fr) | Medicaments therapeutiques/prophylactiques contre des maladies inflammatoires | |
JP2021527669A (ja) | 線維症の軽減又は治療のための組成物及び方法 | |
JP5483775B2 (ja) | 低アルブミン血症改善用組成物 | |
EP3431090A1 (en) | Proliferative agent for bacteria of genus faecalibacterium | |
TW201113023A (en) | Enhancer of activity of nucleic acid analogue | |
CN111544455B (zh) | 益生菌株或其代谢产物用于制备降胆固醇的组合物的用途 | |
KR20180038201A (ko) | 아라자임을 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 | |
CN115919821A (zh) | 胆碱在制备预防肝癌产品中的用途及一种胆碱口服液 | |
WO2006070874A1 (ja) | 低酸素応答促進剤 | |
WO2024079471A1 (en) | Oligosaccharide composition for use in the reduction of the level of ammonia | |
WO2024079472A1 (en) | Oligosaccharide composition for use in the reduction of the level of branched short chain fatty acids | |
JP2023074757A (ja) | ユーコミン酸を含むcd36発現抑制剤 | |
US20170042962A1 (en) | Agent for preventing or ameliorating vascular endothelial malfunction | |
JP5923404B2 (ja) | Trpv4活性抑制剤 | |
JP2008195719A (ja) | 血糖値上昇抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180016591.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11765816 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2793951 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12012501914 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012509620 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1201005240 Country of ref document: TH |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 8870/DELNP/2012 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2011236979 Country of ref document: AU Date of ref document: 20110331 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20127028016 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2011765816 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011765816 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2012146985 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13638358 Country of ref document: US |